Guest: Raymund R. Razonable, M.D.

Host: Darryl S. Chutka, M.D. (@ChutkaMD)

Monoclonal antibodies are laboratory-synthesized and mimic our immune system in fighting harmful pathogens. In addition to convalescent plasma and anti-viral medication, monoclonal antibodies have played an important role in the treatment of infections due to COVID-19. The use of monoclonal antibodies has been shown to shorten the duration of symptoms as well as reduce the risk of hospitalization and mortality due to COVID-19. This podcast will focus on monoclonal antibodies and our guest is Raymund R. Razonable, M.D., from the Division of Infectious Disease at the Mayo Clinic.

Connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

Resource:

• O’Horo J, Challener DW, Anderson RJ, Arndt RF, Ausman SE, Hall ST, Heyliger A, Kennedy BD, Sweeten PW, Ganesh R, Razonable RR, Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease-2019, Mayo Clinic Proceedings (2022), doi: https://doi.org/10.1016/j.mayocp.2022.02.009.